Biomedical Engineering Reference
In-Depth Information
706. Abrahamsson K, Mellander M, Eriksson BO, Holme E, Jodal U, Lindstedt S. 1997.
Cardiac effects of carnitine deficiency induced by antibiotics containing pivalic acid in
children. Cardiol Young 7: 178-182.
707. Holme E, Greter J, Jacobson CE, Lindstedt S, Nordin I, Kristiansson B, Jodal U. 1989. Car-
nitine deficiency induced by pivampicillin and pivmecillinam therapy. Lancet 2: 469-473.
708. Kuntzer T, Reichmann H, Bogousslavsky J, Regli F. 1990. Emetine-induced myopathy
and carnitine deficiency. J Neurol 237: 495-496.
709. Pons R, De Vivo DC. 1995. Primary and secondary carnitine deficiency syndromes.
J Child Neurol 10(Suppl 2): S8-S24.
710. Tune BM. 1994. Renal tubular transport and nephrotoxicity of beta lactam antibiotics:
structure-activity relationships. Miner Electrolyte Metab 20: 221-231.
711. Tune BM, Hsu CY. 1994. Toxicity of cephaloridine to carnitine transport and fatty
acid metabolism in rabbit renal cortical mitochondria: structure-activity relationships.
J Pharmacol Exp Ther 270: 873-880.
712. Watanabe K, Sawano T, Endo T, Sakata M, Sato J. 2002. Studies on intestinal absorption
of sulpiride (2): transepithelial transport of sulpiride across the human intestinal cell line
Caco-2. Biol Pharm Bull 25: 1345-1350.
713. Watanabe K, Sawano T, Jinriki T, Sato J. 2004. Studies on intestinal absorption of
sulpiride (3): intestinal absorption of sulpiride in rats. Biol Pharm Bull 27: 77-81.
714. Wu SP, Shyu MK, Liou HH, Gau CS, Lin CJ. 2004. Interaction between anticonvulsants
and human placental carnitine transporter. Epilepsia 45: 204-210.
715. Verrotti A, Greco R, Morgese G, Chiarelli F. 1999. Carnitine deficiency and hyper-
ammonemia in children receiving valproic acid with and without other anticonvulsant
drugs. Int J Clin Lab Res 29: 36-40.
716. Raskind JY, El-Chaar GM. 2000. The role of carnitine supplementation during valproic
acid therapy. Ann Pharmacother 34: 630-638.
717. Bohan TP, Helton E, McDonald I, Konig S, Gazitt S, Sugimoto T, Scheffner D,
Cusmano L, Li S, Koch G. 2001. Effect of L-carnitine treatment for valproate-induced
hepatotoxicity. Neurology 56: 1405-1409.
718. Kido Y, Tamai I, Ohnari A, Sai Y, Kagami T, Nezu J, Nikaido H, Hashimoto N, Asano M,
Tsuji A. 2001. Functional relevance of carnitine transporter OCTN2 to brain distribution
of L-carnitine and acetyl-L-carnitine across the blood-brain barrier. J Neurochem 79:
959-969.
719. Somogyi A. 1996. Renal transport of drugs: specificity and molecular mechanisms. Clin
Exp Pharmacol Physiol 23: 986-989.
720. Ayrton A, Morgan P. 2001. Role of transport proteins in drug absorption, distribution
and excretion. Xenobiotica 31: 469-497.
721. Shionoiri
H.
1993.
Pharmacokinetic
drug
interactions
with
ACE
inhibitors.
Clin
Pharmacokinet 25: 20-58.
722. Lin JH, Chen IW, Ulm EH, Duggan DE. 1988. Differential renal handling of angiotensin-
converting enzyme inhibitors enalaprilat and lisinopril in rats. Drug Metab Dispos 16:
392-396.
723. Noormohamed FH, McNabb WR, Lant AF. 1990. Pharmacokinetic and pharmacody-
namic actions of enalapril in humans: effect of probenecid pretreatment. J Pharmacol
Exp Ther 253: 362-368.
Search WWH ::
Custom Search